BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 29, 2025
Home » Authors » Katie Pfaff

Articles by Katie Pfaff

Diagnostics firm Karius nets $50M in series A funding round

Aug. 8, 2017
By Katie Pfaff

Reva Medical moves to direct distribution after Boston Scientific agreement expires

Aug. 7, 2017
By Katie Pfaff
Reva Medical Inc. will begin distributing its coronary and peripheral bio-resorbable scaffold devices after Boston Scientific did not renegotiate its agreement and allowed it to expire. Boston Scientific previously held exclusive rights to negotiate distribution, per the 2007 agreement.
Read More

Quanterix closes $8.5M financing for developing biomarker tests

Aug. 4, 2017
By Katie Pfaff

Laminate earns FDA IDE approval for clinical study

Aug. 3, 2017
By Katie Pfaff

Tech reflects our humanity

Aug. 2, 2017
By Katie Pfaff
When my now middle-aged dog was a puppy, I looked into taking him to basic obedience classes. At one of these sessions, a group of newbie pet owners gathered in a room tucked into the back of a pet store. Each came armed with a pocketful of treats or a clicker, hopeful to see results with their pet. As the class went on, some pets obliged their owner’s coaxing to sit or lie down, while others angled for treats. It quickly became apparent that much of the training that was necessary to make a well-behaved dog was actually on the...
Read More

Invitae to acquire Good Start Genetics and Combimatrix in combo stock and cash deal

Aug. 2, 2017
By Katie Pfaff
Genetic information firm, Invitae Corp., plans to acquire both Good Start Genetics Inc., molecular diagnostic company for preimplantation and carrier testing of inherited diseases, and Combimatrix Corp., a prenatal and pediatric diagnostic company, putting itself at the front of the family genetics space. San Francisco-based Invitae entered into definitive agreements with the two companies, which are contingent on several conditions.
Read More

Invitae Corp. acquires Good Start and Combimatrix in combo stock, cash deal

Aug. 2, 2017
By Katie Pfaff
Genetic information firm Invitae Corp. plans to acquire both Good Start Genetics Inc., a molecular diagnostic company for preimplantation and carrier testing of inherited diseases, and Combimatrix Corp., a prenatal and pediatric diagnostic company, putting itself at the front of the family genetics space.
Read More

Chocolate heart study begins, QT Vascular seeks FDA approval

Aug. 1, 2017
By Katie Pfaff

Nico-sponsored ENRICH trial doubles in size

July 31, 2017
By Katie Pfaff

Cochlear's Nucleus 7 pairs with Apple devices to directly process sound

July 28, 2017
By Katie Pfaff
Previous 1 2 … 15 16 17 18 19 20 21 22 23 24 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing